Company News-宜明昂科英文

2026-08-25

ImmuneCare Achieves Dual Milestones for IMC-003 in Clinical Progress: First PAH Patient Dosed, All SAD/MAD Cohorts Completed

These achievements mark significant progress in the program's advancement toward patient validation.

2026-08-22

ImmuneOnco's Amulirafusp Alfa (IMM0306) Receives FDA IND Clearance Phase Ib/II Clinical Trial in Systemic Lupus Erythematosus

This milestone represents a key step forward in the global clinical development of IMM0306 across autoimmune diseases, bringing a potential breakthrough therapeutic option one step closer to millions of SLE patients worldwide.

2026-08-07

ImmuneOnco Subsidiary ImmuneCare Completes Capital Increase of Multi-Million RMB Yuan to Accelerate Non-Oncology Pipeline Development

This capital increase aims to further strengthen ImmuneCare's financial resources and accelerate the research and development of innovative drugs in cardiovascular diseases, such as pulmonary arterial hypertension (PAH), as well as metabolic diseases. This marks the steady implementation of ImmuneOnco's "oncology + non-oncology" dual-engine strategy.

2026-07-27

ImmuneOnco Successfully Convenes Phase II Investigator Meeting of IMC-002 (IMM0306) for Active Systemic Lupus Erythematosus (SLE）

The event aimed to provide a comprehensive overview of the study protocol and unify trial execution standards, laying a solid foundation for the clinical study that is now fully underway.

2026-07-21

IMM2510S，the Subcutaneous Formulation of IMM2510 Completes First Patient Dosing in Phase I Clinical Study, Ushering in a New Era of Convenient Dual-Target Therapy

This milestone is expected to provide a novel treatment option for patients with advanced solid tumors through a more convenient and safer route of administration.